Injectable Morphine Formulations with Oxygen-Barrier Packaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing morphine formulations suffer from instability and degradation due to oxidation, leading to increased impurities and reduced efficacy over time, especially when stored under non-inert conditions.
Innovation Solution
The development of injectable morphine formulations comprising morphine sulfate, an isotonic agent, a buffering agent with anti-oxidative properties, a chelating agent, and a complement to the chelating agent, along with storage in oxygen barrier packaging, which maintains a pH of 4.5 to 5.5 and includes an oxygen scavenger to minimize degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If morphine formulations are stored under non-inert conditions, then ease of storage is improved, but oxidation occurs leading to increased impurities and reduced stability
Solution Approach 1:
The patent applies inert atmosphere by using oxygen barrier packaging materials that create an oxygen-free environment around the morphine formulation. The packaging includes oxygen scavengers and maintains an inert atmosphere during storage, preventing oxidation of morphine while allowing convenient storage conditions.
Solution Approach 2:
The patent introduces oxygen barrier packaging as an intermediary between the morphine formulation and the external environment. This packaging layer acts as a mediator that blocks oxygen transfer, preventing direct contact between oxygen and the formulation while maintaining storage ease.
2Device complexity
If morphine formulations are stored without oxygen barrier packaging, then device complexity is reduced, but oxidation leads to increased impurities above acceptable levels
Solution Approach 1:
The oxygen barrier packaging creates an inert atmosphere that prevents oxidation. The packaging system includes oxygen scavengers and barrier layers that maintain an oxygen-free environment, keeping impurity levels below 1.5% total impurities and 0.2% pseudomorphine throughout the shelf life.
3Ease of manufacture
If morphine formulations use simple packaging without oxygen scavengers, then manufacturing complexity is reduced, but oxidation occurs leading to pseudomorphine levels exceeding 0.2%
Solution Approach 1:
The packaging system incorporates oxygen scavengers that actively remove oxygen from the headspace, creating and maintaining an inert atmosphere. This ensures morphine stability and keeps pseudomorphine levels below 0.2% throughout the shelf life, maintaining formulation reliability.
Solution Approach 2:
Oxygen scavengers act as intermediaries that actively consume oxygen molecules, preventing direct oxidation of morphine. The scavengers are integrated into the packaging system, providing passive protection without complicating the manufacturing process.
4Ease of operation
If morphine formulations are stored in oxygen-permeable containers, then ease of storage is improved, but total impurities increase above 1.5% over time
Solution Approach 1:
The oxygen barrier packaging creates an inert atmosphere that blocks oxygen permeation. The packaging system maintains an oxygen-free environment even during long-term storage, preventing oxidation and keeping total impurities below 1.5% throughout the shelf life.
Solution Approach 2:
The oxygen barrier packaging serves as an intermediary layer that prevents oxygen diffusion into the formulation. This passive barrier system maintains storage convenience while effectively blocking oxygen transfer, keeping impurity levels acceptable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations exhibit enhanced stability, with total impurities limited to less than 1.5% and pseudomorphine levels below 0.2% over extended storage periods, ensuring effective pain management and reduced side effects.
Implementation Method 1
a chelating agent
Implementation Method 2
an oxygen scavenger to minimize degradation
Data Source
AI summary
Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.